Camurus raises full year 2020 revenue guidance
Lund, Sweden — 23 June 2020 — Camurus today announced revised full year 2020 guidance for the company’s revenue and product sales. Camurus’ guidance for net revenue is increased to SEK 340–380 million from SEK 290–330 million with estimated product sales of SEK 310–340 million, previously SEK 240–280 million. The improvements are driven by increasing market shares of Buvidal[®] for treatment of opioid dependence in Europe and Australia. Operating expenses are expected amount to SEK 570–610 million, as communicated previously (including a provision for legal costs for the recently